Co-Diagnostics, Inc. announced sales of its screening test designed to identify the presence of the novel coronavirus that originated in China. Co-Diagnostics Logix Smart 2019-nCoV polymerase chain reaction (PCR) tests use highly specific targeting and the company’s patented CoPrimer technology platform to detect the strain of coronavirus first discovered in Wuhan, China on Dec. 31, 2019.
The test is compatible with various manufacturers’ PCR devices that are commonly used and is immediately available on a Research Use Only (RUO) basis to thousands of laboratories throughout the world.
Dwight Egan, Co-Diagnostics CEO, commented, “We believe the way that Co-Diagnostics can be most helpful in this ongoing situation is by providing diagnostic solutions that are affordable and accessible in any market in the world. Our mandate includes supporting as many markets as possible in a public health crisis, and taking a test from design to commercialization in under three weeks underscores this commitment.”
